Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia

Authors: Marina Dokic, Ivana Urosevic, Ivanka Savic, Borivoj Sekulic, Aleksandar Savic, Ivana Milosevic, Nebojsa Rajic

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Excerpt

Chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL) are the most common types of leukaemia in elderly. The characteristic of CML is Philadelphia chromosome, became of translocation of chromosome 9 and 22 and fusion of bcr-abl gene. Result of fusion bcr-abl gene is activation tyrosin-kinase and uncontrolled proliferation of myeloid cells [1]. CLL characteristics are low proliferative activity and accumulation of monoclonal B lymphocytes in bone marrow, lymph nodes and other organs which are resistant to apoptosis. Simultaneous occurrence of CML and CLL is extremely rare. We report here a case of patient in whom CLL developed during the treatment of CML with imatinib mesilate. …
Literature
1.
Bhagavathi S, Borromeo V, Desai H, Crisan D (2008) Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. Ann Clin Lab Sci 38(4):405–409PubMed
2.
Nagao T, Takahashi N, Kameoka Y, Noguchi S, Shinohara Y, Ohyagi H, Kume M, Sawada K (2013) Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Intern Med 52(22):2567–2571CrossRefPubMed
3.
Serpa M, Bendit I, Seguro F et al (2010) Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. Acta Haematol 124:105–109CrossRefPubMed
4.
Gargallo P, Cacchione R, Chena C et al (2005) Chronic lymphocytic leukemia developing in a patient with chronic myeloid leukemia: evidence of distinct lineage-associated genomic events. Cancer Genet Cytogenet 161:74–77CrossRefPubMed
5.
Salim R, Wang L, Lin K, Clark RE (2002) Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia. Leuk Lymph 43:2225–2227CrossRef
6.
Chang H, Sutherland R, Nayar R, Li D, Kamel-Reid S, Mile MA et al (2004) Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting. Cancer Genet Cytogenet 152:146–148CrossRefPubMed
7.
Kumar N, Ahluwalia J, Malhotra P, Sachdeva MS (2013) Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia-accelerated phase: a rare case with review of the literature. Indian J Pathol Microbiol 56:303–305CrossRefPubMed
8.
Bartik MM, Welker D, Kay NE (1998) Impairments in immune function in B cell chronic lymphocytic leukemia. Semin Oncol 25:27–33PubMed
9.
Hisada M, Biggar RJ, Greene MH, Fraumeni JF, Travis LB (2001) Solid tumors after chronic lymphocytic leukemia. Blood 98:1979–1981CrossRefPubMed
10.
Jin HH, Won HJ, Myong SC, Lee M, Soon CW (2003) Acute lymphoblastic leukemia without Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. Am J Hematol 74:218–220CrossRef
11.
Zhang X, Ji L, Liu S, Wang J (2003) Ph-negative acute lymphocytic leukemia occurring after interferon therapy for Ph positive chronic myelocytic leukemia. Leuk Res 27:367–369CrossRefPubMed
12.
Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A et al (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118:4353–4358CrossRefPubMedPubMedCentral
13.
Crescenzi B, Sacchi S, Marasca R et al (2002) Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia. Leukemia 16:955–956CrossRefPubMed
14.
Amrein PC (2011) The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leuk Lymph 52:754–763CrossRef
15.
Allen JC, Talab F, Zuzel M, Lin K, Slupsky JR (2011) c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood 117:2414–2422CrossRefPubMed
16.
Contri A, Brunati AM, Trentin L et al (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115:369–378CrossRefPubMedPubMedCentral
17.
Amrein PC, Attar EC, Takvorian T et al (2011) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 17:2977–2986CrossRefPubMedPubMedCentral
18.
Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers SL, Paquette RL, O’Dwyer ME (2002) Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months’ experience. Blood 100(2):435–441CrossRefPubMed
Metadata
Title
A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia
Authors
Marina Dokic
Ivana Urosevic
Ivanka Savic
Borivoj Sekulic
Aleksandar Savic
Ivana Milosevic
Nebojsa Rajic
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0638-2

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue

Correspondence

Cholestasis in a Patient of Multiple Myeloma: A Rare Occurrence of Bortezomib Induced Liver Injury

Case Report

Glioblastoma Multiforme in a Post Allogeneic Stem Cell Transplant Patient. A Case Report and Literature Review of Post Transplant Neurological Tumors

Case Report

CD56 Negative Aggressive T Cell Large Granular Lymphocytic Leukemia

Case Report

Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon

Correspondence

Occurrence of Double Monoclonal Bands on Protein Electrophoresis: An Unusual Finding

Short Communication

Leukemia in Patients with Klinefelter Syndrome: A Report of Two Cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits